Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients

Table 2 Pathological features of 7 patients with Pancreatic Ductal Adenocarcinoma included in the immunohistochemistry analysis

	Age	Gender	Tumour type	Tumour Size (cm)	Tumour Grading	Tumour stage	Margins of resection
1?V-15660	78	m	PDAC	3.05	G2-G3	IIB	R1
1?M-17396	69	m	Mucinous PDAC	3	G1	IIB	R0
1?M-17536	53	f	PDAC	3	G2-G3	IIA	R0
1?T-17785	65	m	PDAC	3	G2-G3	IIB	R0
193551-10	73	m	PDAC	1,8	G1	IIB	R0
I2011-010518	51	f	PDAC	2,5	G2	IIB	R0
I2012-016339	78	f	PDAC	2,4	G2	IIB	R0

G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated. R0: negative resection margins; R1:microscopic positive resection margins. Tumor stage sec. AJCC 2010.

ISSN: 1479-5876